Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Inclusion Criteria:

- Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic
score

- Evidence of colonic ulcerative colitis activity on endoscopy

Exclusion Criteria:

- Within 30 days prior to randomization, receipt of any of the following for the
treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus,
tofacitinib, thalidomide), a non-biologic investigational therapy or an approved
non-biologic therapy in an investigational protocol

- Within 60 days prior to randomization, receipt of any of the following: Infliximab,
adalimumab, golimumab, certolizumab or any other investigational or approved biologic
agent

- Any prior exposure to natalizumab, efalizumab, or rituximab